Altimmune to Participate in Two Upcoming Investor Conferences
Altimmune (Nasdaq: ALT) said company management will attend two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 10:00 a.m. ET, and a Jefferies Global Healthcare Conference fireside chat on November 20, 2025 at 9:30 a.m. GMT. Management will be available for one-on-one meetings. Both sessions will be webcast and accessible via the Events section of the company's website.
Altimmune (Nasdaq: ALT) ha dichiarato che la direzione della società parteciperà a due conferenze per investitori a novembre 2025: un talk informale al Stifel 2025 Healthcare Conference il 12 novembre 2025 alle 10:00 ET, e un talk informale al Jefferies Global Healthcare Conference il 20 novembre 2025 alle 9:30 GMT. La dirigenza sarà disponibile per incontri individuali. Entrambe le sessioni saranno trasmesse in webcast e accessibili dalla sezione Eventi del sito web dell'azienda.
Altimmune (Nasdaq: ALT) dijo que la dirección de la empresa asistirá a dos conferencias para inversionistas en noviembre de 2025: una charla junto al fuego en la Stifel 2025 Healthcare Conference el 12 de noviembre de 2025 a las 10:00 a. m. ET, y una charla junto al fuego en la Jefferies Global Healthcare Conference el 20 de noviembre de 2025 a las 9:30 a. m. GMT. La dirección estará disponible para reuniones individuales. Ambas sesiones serán transmitidas en webcast y accesibles desde la sección Eventos del sitio web de la empresa.
Altimmune (나스닥: ALT)는 2025년 11월에 두 차례 투자자 회의에 경영진이 참석할 것이라고 밝혔습니다. 11월 12일 2025년 10:00 a.m. ET에 열리는 Stifel 2025 Healthcare Conference의 파이어사이드 채팅과 11월 20일 2025년 9:30 a.m. GMT에 열리는 Jefferies Global Healthcare Conference의 파이어사이드 채팅이 그것입니다. 경영진은 일대일 미팅을 위해 대기합니다. 두 세션 모두 webcast로 중계되며 회사 웹사이트의 행사(Event) 섹션에서 확인할 수 있습니다.
Altimmune (Nasdaq : ALT) a déclaré que la direction de l'entreprise assistera à deux conférences pour investisseurs en novembre 2025 : un Fireside Chat lors de la Stifel 2025 Healthcare Conference le 12 novembre 2025 à 10h00 ET, et un Fireside Chat lors de la Jefferies Global Healthcare Conference le 20 novembre 2025 à 9h30 GMT. La direction sera disponible pour des réunions en tête-à-tête. Les deux sessions seront diffusées en webcast et accessibles via la section Événements du site Web de l'entreprise.
Altimmune (Nasdaq: ALT) sagte, dass das Management des Unternehmens an zwei Investorenkonferenzen im November 2025 teilnehmen wird: ein Fireside Chat bei der Stifel 2025 Healthcare Conference am 12. November 2025 um 10:00 Uhr ET und ein Fireside Chat bei der Jefferies Global Healthcare Conference am 20. November 2025 um 9:30 Uhr GMT. Das Management steht für Einzelgespräche zur Verfügung. Beide Sitzungen werden per Webcast übertragen und sind über den Bereich Veranstaltungen auf der Website des Unternehmens zugänglich.
Altimmune (ناسداك: ALT) قالت إدارة الشركة ستحضر مؤتمرين للمستثمرين في نوفمبر 2025: دردشة بجلسة النار في مؤتمر Stifel 2025 Healthcare Conference في 12 نوفمبر 2025 الساعة 10:00 صباحًا بتوقيت شرق الولايات المتحدة، ودردشة Fireside في Jefferies Global Healthcare Conference في 20 نوفمبر 2025 الساعة 9:30 صباحًا بتوقيت GMT. ستتوافر الإدارة لعقد اجتماعات فردية. كلا الجلستين ستنقلان عبر الإنترنت ( webcast ) ويمكن الوصول إليهما من قسم الفعاليات في موقع الشركة على الويب.
- None.
- None.
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for one-on-one meetings at the following investor conferences:
- Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025
Fireside Chat at 10:00 a.m. ET
- Jefferies Global Healthcare Conference
Thursday, November 20, 2025
Fireside Chat at 9:30 a.m. GMT
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Elliot Fox
Real Chemistry
efox@realchemistry.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) present at the Stifel 2025 Healthcare Conference?
What time is Altimmune's (ALT) fireside chat at the Jefferies Global Healthcare Conference?
How can investors watch Altimmune (ALT) conference presentations in November 2025?
Will Altimmune (ALT) management be available for meetings at the November 2025 conferences?
Which investor conferences will Altimmune (ALT) attend in November 2025?
